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The Prostate Cancer Risk Management Programme (PCRMP) launched in November 2002 provides guidelines for general
practitioners (GPs) on age-specific prostate-specific antigen (PSA) cutoff levels in asymptomatic men. The impact of the PCRMP on
GP referrals is unknown. This study investigates whether there was a change in the proportion of asymptomatic men with raised PSA
levels (X3 ng ml1) who were referred to urologists since the launch of the guidelines. Sixty-nine general practices in four areas of
England and the main pathology laboratory in each area, which had participated in our previous research, were asked to provide data.
Forty-eight practices (70%) provided retrospective data on urological referrals in men who had a PSA test taken in the periods 1
December 2001 to 31 May 2002 (pre-launch) and 1 December 2003 to 31 May 2004 (post-launch). Data on referrals were
completed for 709 (79%) out of 898 and 1040 (90%) out of 1157 raised records pre- and post-launch, respectively. The percentage
of men with raised PSA levels who were asymptomatic was similar in both time periods (19–20%) and the proportion referred to
urologists according to the PCRMP guidelines did not increase significantly over time (24% pre-launch and 29% post-launch, P¼ 0.42).
The referral rate was lower than expected if the guidelines had been followed. The influence of the guidelines seems to have been
low. At the time of data collection, 56% (112 out of 200) of GP partners reported that they were aware of receiving the PCRMP
pack. To ensure future, effective implementation of guidelines requires evaluation.
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The rate of prostate-specific antigen (PSA) testing for prostate
cancer has been increasing in the United Kingdom since the early
1990s (Gavin et al, 2004; Melia et al, 2004; NHS Cancer Screening
Programmes, 2004). Part of this increase will be due to testing for
prostate cancer in asymptomatic men. In 28 areas of England and
Wales, using data collected from 1 December 2001 to 31 May 2002,
we had estimated the annual rate of PSA testing by general
practitioners (GPs) in men aged 45–84 years with no previous
diagnosis of prostate cancer to be 6%, with the rate of asymptomatic
testing being 2% (Melia et al, 2004). In September 2002, the NHS
Prostate Cancer Risk Management Programme (PCRMP) was
launched (NHS Cancer Screening Programmes, 2008). All GPs and
urologists in England were sent the PCRMP information pack,
which contained materials to help men requesting a PSA test to
make an informed choice about the benefits and potential harms of
screening. The effect of the programme on knowledge and intention
to be tested has been studied (Watson et al, 2006). The programme
also provided guidelines on the age-specific PSA cutoff levels for
urological referral in asymptomatic men: aged 50–59 years
X3 ng ml1, 60–69 years X4 ng ml1 and 70 years or more
45 ng ml1. The impact of the initiative on referral rates for men
with a raised PSA is unknown.
The results presented in this paper compare the rates of
urological referral between two 6-month periods before and after
the introduction of the PCRMP, specifically in asymptomatic men.
A randomised controlled trial could not be conducted because of
the nationwide distribution of PCRMP packs. Data from our
previous study in England (Melia et al, 2004) provided a baseline
for the present study. Additional data on PSA testing were
collected from a subset of the pathology laboratories and data on
referrals from selected general practices. A full report on the study
is available on the NHS Cancer Screening Programmes website.
MATERIALS AND METHODS
Study areas and selection of general practices
The pathology laboratory at the main hospital in each of the study
areas Chichester, Sutton & Merton, Truro and York, which had
provided timely data in the previous study (Melia et al, 2004),
agreed to take part in the study. Data were collected on PSA
requests from general practices in our previous study. The criteria
for selecting the original group of practices were that they should
routinely send all NHS PSA requests to the laboratory at the main
hospital in their area, and that all GP partners should provide
signed consent.
These practices were invited to participate in the present
study. Each GP partner completed a one-page questionnaire
on demographic data, membership of the Royal College of
General Practitioners (MRCGP) and awareness of receiving the
PCRMP pack.
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Data collection on PSA requests and referrals
Data on PSA requests from the pathology laboratories were
collected for the period 1 December 2001 to 31 May 2004. The
variables were specimen number, date of test, name and date of
birth of man receiving test, NHS number and hospital number,
name of GP and practice, and total PSA level (ng ml1). Patient-
based set of records was formed.
It was not feasible to ask the GPs to provide retrospective data
on referrals for the full 212 year period, so data were collected for
one period pre-launch (1 December 2001 to 31 May 2002) and
another period post-launch (1 December 2003 to 31 May 2004).
The first time period was chosen because data had already been
collected on reason for test (Melia et al, 2004). The second time
period was chosen at the same time of year to avoid confounding
from seasonal variation in rate of testing and to ensure that GPs
would have had time to assess and actively use the PCRMP packs
distributed in September 2002.
Referral data were collected on all men with a raised PSA value
(X3 ng ml1), all men with more than one test over the two time
periods and a random 25% sample of men with a single low PSA
value (o3 ng ml1). Thus, data collection concentrated mostly on
records with PSA levels above the minimum PCRMP age-specific
level of 3 ng ml1 to reduce the number of patient records to be
searched. A pro forma was prepared for each man, listing his PSA
tests (Appendix A). The form included definitions of the reasons for
tests as used in the previous study (Melia et al, 2004). There were
four categories: men with no previous diagnosis of prostate cancer
who were asymptomatic, symptomatic or being re-tested, and men
already diagnosed with prostate cancer. Data on urological referrals
included the date of referral and hospital name. Reasons for non-
referral or for not being able to complete a pro forma were reported.
Each general practice was paid a flat rate per patient record checked.
It was not feasible to ask retrospectively whether the PCRMP
pack had been used during patient consultations in the post-
launch period because this was not recorded in patient notes.
A questionnaire on local initiatives was sent to the consultant
urologists, chairmen of the Primary Care Trusts and Directors of
Public Health. However, no initiatives were identified up to the end
of the post-launch study period.
Sample size
The sample size was selected to give 80% power to detect, at the 5%
level of significance, a difference of 70 vs 83% in the proportions
referred before and after the distribution of leaflets. Data collection
resulted in a larger population being studied than originally
planned with a larger number of PSA tests but a lower rate of
urological referral (overall o30% in both study periods). The
larger population resulted in the study being powered to detect
changes from 20 to 40% in the proportion of men referred.
Analysis
Poisson regression analyses were used to study the relation
between GP partners’ awareness of receiving the PCRMP pack and
GP characteristics, and the distribution of the proportion of GP
partners per practice aware of the PCRMP packs has been studied.
Analyses were conducted on the first PSA test recorded for each
man in each of the pre- and post-launch periods. The definition of
‘first recorded test’ is restricted to PSA tests reported within a strict
time period and does not refer to the first PSA test ever taken for
an individual. The men were aged 45–84 years at time of their first
test, had a PSA test within either of the two time periods pre- and
post-launch, and were not reported dead or no longer registered at
their study practice.
The analyses of referral rates in this paper are restricted to men
who were reported to be asymptomatic at the time of their PSA test
in each period. The referral rate was defined as the proportion of
asymptomatic men with no previous diagnosis of prostate cancer
who were referred to urologists by their GPs following a PSA test.
The proportions of men referred were studied within groups of
men categorised by the age-specific PSA cutoff levels defined by
the PCRMP.
In the analyses of data on men’s individual records, it was not
possible to study variation in referral rates by practice, or between
GPs within practices, because of the small number of men being
referred. Social deprivation was not included in the analyses, as
individual-based data were not collected on social class or
postcode, which could have been linked to a social deprivation
index.
RESULTS
Uptake of practices
Of 71 practices participating in the previous study (Melia et al,
2004), 2 no longer existed in the post-launch period, so 69 were
invited, of which 48 (70%) took part in the present study. The
uptake rate was 75% or more in all areas except Truro, which had
an uptake rate of 57% (Fisher’s exact test P¼ 0.47 comparing the
response rate in Truro with the other areas). The invited practices
represented 33% of those invited to participate in the previous
study. The uptake was low because many non-responding practices
were ineligible, that is, did not use the laboratory for all their PSA
tests.
The total male populations aged 45– 84 years registered at the
participating practices were 67 162 and 70 658 men in the pre- and
post-launch periods, respectively. There were a total of 200 GP
partners at these practices at the time of data collection. The
proportions of practices with 1, 2– 4, 5– 6 and 7 –8 or more GP
partners were 10% (5), 42% (20), 40% (19) and 8% (4),
respectively.
GP awareness of receiving the PCRMP pack
Awareness of receiving the PCRMP pack was acknowledged by
56% (112 out of 200) of GP partners at the time of data collection
with 24 unaware of the pack and 64 who did not know. The
proportion of GP partners per practice who were aware of the
PCRMP pack varied independently of size of practice. In the five
practices with one partner, only one was aware of the PCRMP
pack. In the 43 practices with two or more partners, 28 (65%) had
X50% of partners aware of the PCRMP pack. Of those with more
than one partner, there were 12 (28%) practices where all partners
were aware of the pack. In Poisson regression, awareness reported
by the GPs did not differ significantly between areas and it was not
related to age, gender, MRCGP, number of years working as a GP
or number of sessions per week.
Data completeness
Out of 2494 and 3209 PSA requests in the pre- and post-launch
periods, respectively, there were 12 records with missing data on
PSA value or patient name, and one record with gender coded
female. Record linkage led to 2318 and 3030 men with at least one
PSA test in the pre- and post-launch periods, respectively (Table 1).
Excluding men reported to be deceased or no longer registered at
the practices resulted in pre-launch 515 (36.3%) out of 1420 men
with low records and 709 (79.0%) out of 898 men with raised PSA
levels available for analysis including those with multiple tests and
post-launch 607 (32.4%) out of 1873 and 1040 (89.9%) out of 1157,
respectively (Table 1). Data requested on the pro forma on ethnic
group and family history of prostate cancer could not be analysed,
as high proportions of records had missing data (430% for
ethnicity and 86% for family history).
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Reason for test
The percentage distributions of reason for test were similar in both
time periods (Table 2). A higher proportion of men with low PSA
levels were asymptomatic compared with men with raised PSA
levels (pre-launch: 38 and 19%, respectively, w1
2¼ 56.3, Po0.001;
post-launch: 39 and 20%, respectively, w1
2¼ 71.2, Po0.001).
Urological referrals in asymptomatic men
The proportions of asymptomatic men referred among those with
raised PSA levels did not increase significantly from the pre- to
post-launch period (13.7 and 18.2%, respectively, Table 3). There
were no referrals in asymptomatic men with low PSA levels. There
was also no significant difference in the referral rates by area
(Fisher’s exact test P¼ 0.33). Among those not referred, the most
frequent reason was PSA too low (87%, 347 out of 400, post-
launch), and re-testing scheduled by GP in general practice (7%, 29
out of 400, post-launch, Table 3). In the raised PSA group,
additional reasons for non-referral included serious comorbidity.
Analysis of referral according to the PCRMP age-specific cutoff
levels, restricted to men aged 50–84 years, showed that in the pre-
launch period no men were referred with PSA levels below the
PCRMP cutoff levels, and there was no significant increase in the
proportion of men referred over time in this group (0.0– 1.6%,
Fisher’s exact test P¼ 0.07). There was also no significant increase
in the proportion of men referred among those with PSA levels
above the cutoff levels (24.0–29.4%, P¼ 0.42, Table 4). No men were
referred in the age group 45–49 years below the age range defined
by the PCRMP (Table 4). There was also no significant increase in
the proportion referred with age (Fisher’s exact test P40.20).
Of all 55 men referred, 45 (82%) were referred within 2 months of
their test. In pre-launch findings, the median PSA value associated
with referral increased with age from 5.2 ng ml1 in 50- to 59-year
olds to 6.8 ng ml1 in 70- to 84-year olds. Post-launch findings were
similar with the median PSA value associated with referral increasing
from 6.2 ng ml1 in 50- to 59-year olds to 13.0 ng ml1 in 70- to 84-
year olds. Five men post-launch with PSA levels below the PCRMP
age-specific cutoffs were referred: in these men, PSA levels ranged
from 3 to 4.9 ng ml1 in the age range 60–84 years).
Among asymptomatic men not referred post-launch but having
a PSA level that was above the PCRMP age-specific guidelines, 18
aged 50 –59 years had levels ranging from 3 to 8.5 ng ml1, 29 aged
60–69 years had levels ranging from 4 to 9.5 ng ml1 and 30 aged
70–84 years had levels ranging from 5.1 to 23.6 ng ml1. When
these data were restricted further to those non-referrals for which
the GPs reported the PSA level to be too low for referral, the ranges
were 3–5.2, 4 –8.9 and 5.3–7.5 ng ml1, respectively.
Table 1 Number of men for whom data were collected and counts of exclusions by time period and whether the PSA level was low (o3 ng ml1) or
raised (X3 ng ml1)
Pre-launch, 1 December
2001 to 31 May 2002
Post-launch, 1 December
2003 to 31 May 2004
Total
No. with 1st test
low record
No. with 1st test
raised record Total
No. with 1st test
low record
No. with 1st test
raised record
No. of men aged 45–84 years before stratified sampling 2318 1420 898 3030 1873 1157
Reasons for exclusions from laboratory data files
Removed by sampling procedure 848 0 1199 0
One practice reduced workload 9 23 11 32
At one lab, GPs only notified of rounded values,
so some PSA levels were classified as low
NA 20 NA 0
No. of men aged 45–84 years after stratified sampling 1418 563 855 1788 663 1125
Reasons for exclusion from data analysis after data collection from general practices
Men’s records not available due to death or no longer
registered at practice
194 48 146 141 56 85
No. of men aged 45–84 years alive and still registered at practice 1224 515 709 1647 607 1040
Of which, no. with a single test 1111 1520
GP, general practitioner; PSA, prostate-specific antigen.
Table 2 Distribution of men by reason for test, time period and whether they had a low (o3 ng ml1) or raised (X3 ng ml1) PSA level
Pre-launch, 1 December
2001 to 31 May 2002
Post-launch, 1 December
2003 to 31 May 2004
Low recordsa Raised records Low recordsa Raised records
Reason for test No. % No. % No. % No. %
Asymptomatic 194 37.7 131 18.5 234 38.6 203 19.5
Symptomatic 188 36.4 284 40.1 201 33.1 445 42.8
Re-test 56 10.9 220 31.0 56 9.2 273 26.3
Prostate cancer already diagnosed 72 14.0 68 9.6 100 16.5 103 9.9
Not known 5 1.0 6 0.8 16 26.4 16 1.5
Total included in data collection 515 100 709 100 607 100 1040 100
Significance of difference in distribution of
reason for test between low and raised records
w4
2¼ 100.3, Po0.001 w42¼ 132.9, Po0.001
PSA, prostate-specific antigen. No significant differences between the two time periods were found in the distribution of reason for test among men with low or men with raised
PSA levels. aBased on sub-sample, see Table 1.
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DISCUSSION
The aim of this study was to investigate the impact of the PCRMP
guidelines for age-specific cutoff levels for PSA levels in
asymptomatic men on urological referrals. No significant change
in the proportion of asymptomatic men being referred to
urologists following a PSA test was observed between the two
time periods before and after the launch of the PCRMP. The
proportions referred were lower than that anticipated. Thus,
the influence of the PCRMP guidelines seems to have been low.
The relation of the PCRMP guidelines to decisions about referral
could not be studied retrospectively because these data are not
routinely recorded. However, at the time of data collection, 56% of
GP partners in the study reported being aware that they had
received the PCRMP packs, and the proportion of GP partners
aware per practice showed a wide variation from 0 to 100%.
GPs adopted a varied but cautious approach to referral, with all
non-referral considered by their GP to have a low PSA level having
levels below 10 ng ml1. It is not know why some GPs chose to take
a PSA test when the patient had comorbidities, which influenced
the decision not to refer them. It was not feasible to collect this
information, as the GP consulting at the time of the PSA test was
not necessarily the one providing the retrospective data. No local
guidelines for referral of asymptomatic men were reported. Review
of the guidance provided in the study laboratories’ pathology reports
was primarily concerned with symptomatic men and those already
diagnosed with prostate cancer. Re-testing was the most frequent
management in non-referrals in men with raised PSA levels.
The main limitations of the study concern the choice of study
design, the uptake of the practices, the completeness of data
collection and variation in laboratory assays to measure PSA. It was
not possible to conduct a randomised controlled trial because the
programme was launched nationwide. The observational design
used may have been affected by local and national influences.
However, if the PCRMP guidelines had had a strong impact on PSA
testing and referrals, this should have been detected.
The data collected on GP partners’ awareness of the PCRMP
packs are limited because knowledge and views on the guidelines
were not studied in detail. As these data were only available at the
time of data collection, it was not appropriate to link them to the
retrospective referral data: awareness among GP partners does not
imply that the PCRMP packs were used during consultations, and
the GPs helping with data collection from patient notes were not
always those who had made the referral decisions. It was also not
possible to study men’s experiences of PSA testing as has been
done in one study (Evans et al, 2007).
Data collection on referrals was restricted to two identical times
of year in 2001/2002 and 2003/2004. This controlled for time of
Table 3 Number of urological referral and reasons for non-referral in asymptomatic men by time period and whether they had a low (o3 ng ml1) or
raised (X3 ng ml1) PSA level
Distribution of non-referrals by reason
Total
number
Referrals
Non-
Significance
of difference
in % referred
between men with
low and raised
PSA
too
Re-test scheduled and
initiated by
Serious Lost to Not
of men n % referrals PSA records low GP practice Urologist comorbidity Other follow-up known
Pre-launch
Low PSA records 194 0 0 194 w1
2¼ 28.2 187 3 0 0 3 0 1
Raised PSA levels 131 18 13.7 113 Po0.001 71 21 2 6 3 3 7
Total 325 18 5.5 307 258 24 2 6 6 3 8
Post-launch
Low PSA records 234 0 0 234 w1
2¼ 46.6 230 3 0 1 0 0 0
Raised PSA levels 203 37 18.2 166 Po0.001 117 26 4 6 7 1 5
Total 437 37 8.5 400 347 29 4 7 7 1 5
GP, general practitioner; PSA, prostate-specific antigen. Significance: no significant differences between the two time periods in distributions of referral and non-referral for either
low or raised PSA levels.
Table 4 Proportion of asymptomatic men referred pre- and post-launch aged 45–84 years grouped by PSA level and age
Age (years)
45–49 50–59 60–69 70–84
Total % men referred
below and above
age-specific cutoff
PSA level (ng ml1) o3 X3 o3 X3 o3 X3–o4 Total o4 Total X4 o3 X3–p5 Total p5 Total 45 Below Above
Pre-launch
% 0 0 0 37.5 0 0 0 22.9 0 0 0 16.7 0 24
No. referred 0 0 0 6 0 0 0 8 0 0 0 4 0 18
Total no. of men 10 0 65 16 61 19 80 35 58 37 95 24 250 75
Post-launch
% 0 0 0 18.2 0 3.4 0.9 31 0 6.5 2.9 33.3 1.5 28.6
No. referred 0 0 0 4 0 1 1 13 0 4 4 15 5 32
Total no. of men 10 3 60 22 86 29 115 42 78 62 140 45 325 112
PCRMP, Prostate Cancer Risk Management Programme; PSA, prostate-specific antigen. Results in bold relate to PCRMP guidelines for referral: aged 50 –59 years X3 ng ml1,
aged 60–69 years X4 ng ml1 and 70 years or more 45 ng ml1. No significant difference in the proportion of referrals between pre- and post-launch periods.
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year, and the second period allowed GPs a year after the launch to
take on board the PCRMP guidelines. It was not feasible to ask GPs
to provide data for a longer time period.
The practices were chosen from our previous study to enable the
use of data already collected. The practices in the previous study were
not a random sample, representing just more than 30% of those
recorded as using the pathology laboratories. The practices in the
study of referral rates represent a smaller proportion of single-handed
practices (10%) than nationally (27% in 2004) (Department of Health,
2005). They also represented a narrow range of social deprivation
scores linked to practice postcodes: the mean (±s.d.) Townsend
scores for the participating practices were 2.62±0.08, 1.46±0.99,
1.32±0.50 and 2.16±0.83 in Chichester, Sutton & Merton, Truro
and York, respectively. It is possible that the participating GPs were
more likely to test for PSA than GPs in more deprived areas, but it is
unclear what effect the selection bias could have had on urological
referrals and use of the PCRMP guidelines.
Data on referral were incomplete for men who had died or who
were no longer registered at the practices, as their notes were
not available. The proportions were higher pre-launch than
post-launch (13.7%, 194 out of 1418, and 7.9%, 141 out of 1788,
respectively, w1
2¼ 28.4, P¼ 0.0001). Men with missing data were
older and had higher levels of PSA compared with men not missing
these data. Thus, those excluded from the analyses were more
likely to have been symptomatic or diagnosed with prostate cancer
than men for whom data were completed. The results for referral
rates in asymptomatic men are less likely to have been affected by
these biases than in men tested for other reasons.
All of the laboratories participated in the Quality Assurance
scheme for PSA measurement (Milford Ward et al, 2001). Their
methods of measurement were Bayer Immunol, Bayer Centaur and
DPC Immunite (two laboratories). Variation in bias of PSA
measurements by these assays (Roddam et al, 2006) is likely to
have affected a very small proportion of men, as the GPs were not
using the same cutoff levels. The reliability of the referral data was
strengthened by asking for a date of referral and consultant name.
Analysis of reason for test by PSA level showed that low levels were
associated with asymptomatic testing, as has been found in
screening trials (De Koning et al, 2002). The distribution of reason
for test in men with low and raised PSA levels was also as expected
in both time periods of the study (Table 2).
Few studies have reported on urological referral rates in general
practice linked to specific PSA tests, partly because there is
considerable workload involved in retrospectively searching
patient notes. In the United States (Dyche et al, 2006), referral
rates were studied from 1998 to 2004 in men aged X75 years with
no previous prostate cancer diagnosis attending one centre in
Iowa: in those with PSA levels between 0.1 and 4.0 ng ml1, 28.6%
were referred, and in those with PSA levels 44.0 ng ml1, 52%
were referred. For the comparable populations defined by age and
PSA level in our study, 7% (8 out of 120) and 30% (56 out of 186)
were referred, respectively, pre-launch, representing the period
2001/2002.
As the rate of PSA testing continues to increase in England, and
there is no standard management of tests in asymptomatic men,
evaluation of the PCRMP guidelines is essential (Watson et al,
2006). Without routine, standardised data on reasons for PSA tests
in general practice, it will be impractical to monitor trends in use
of the PSA test, and its impact on GP workload and detection of
prostate cancer. There is an urgent need for evaluation to ensure
future, effective implementation of guidelines.
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Appendix A
PSA Referral Study: Code Sheet Instructions
Code for Reason for Test
Asym ASYMPTOMATIC MEN WITH NO PRECEDING DIAGNOSIS OF PROSTATE CANCER
Men who request screening, but not those who have attended because of prostate symptoms
Men offered PSA screening or re-screening as part of general health check eg Well Man Clinic
Opportunistic test by GP while patient attended for health reasons unrelated to prostate cancer
(use of these categories should be independent of any findings from rectal examination)
Sym SYMPTOMATIC MEN WITH NO PRECEDING DIAGNOSIS OF PROSTATE CANCER
Men attending because of concerns about prostate symptoms
Re-test RETEST OF MEN WITH NO PRECEDING DEFINITIVE DIAGNOSIS OF PROSTATE CANCER
Men undergoing review who had a previous negative biopsy, but raised PSA
Men undergoing review because previous PSA level within the normal range, but higher than average
PrCa MEN WITH PRECEDING DEFINITIVE DIAGNOSIS OF PROSTATE CANCER
Men undergoing regular PSA measurement as a marker of disease activity
NK Not known
PSA Referral Study: GP Patient Proforma GP Practice Name: Practice ID:
Patient Name: DOB Sex: Name of GP:
PLEASE COMPLETE by circling answers and completing the table. Please indicate if any corrections are needed to pre-coded data eg.
Reason for Test
African or African-
Caribbean origin:
NO YES NOT KNOWN Family history of
prostate cancer:
NO YES NOT KNOWN
Date of PSA Test Total PSA
Result
(ng/ml)
Reason
for Test
(see code sheet)
NO urological referral
following test: Reason
(see code sheet)
YES – urological
referral
following test
Date Hospital Consultant NHS/
Private
If reason for NO urological referral is ‘Other’ please describe yyyyyyyyyyyyyy..
If patient has been diagnosed with prostate cancer please give date of diagnosisyy/yy../yyy.
IF UNABLE TO COMPLETE FORM (please circle)
Patient has: Moved Died Other If ‘Other’ give reasonyyyyyyyyyyyyy.
THANK YOU Please return to the Cancer Screening Evaluation Unit, Institute of Cancer Research, SM2 5NG.
Code for Reason for No Referral
1 – PSA too low (no known Prostate Cancer diagnosis)
2 – Patient diagnosed with prostate cancer prior to this test
3 – Patient has other serious co-morbidity including senility/old age
4a – Re-test was scheduled, no previous referral (no known Prostate Cancer diagnosis)
4b – Re-test was scheduled, previous referral (no known Prostate Cancer diagnosis)
5 – Other
6 – Lost to follow up
NK – Not known
Example of a Patient Proforma
Urological referral in general practice
J Melia et al
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